PTPRC and acute myeloid leukemia: We followed the development of AML and by five weeks post-transplant, Cbfb+/56MFbxo9−/− mice had on average 69.6% tumor PB compared to only 25% in the Cbfb+/56MFbxo9+/+, indicating that tumors with decreased Fbxo9 develop more rapidly (Figure 5B.)We also observed an earlier effect on normal hematopoiesis, as seen in the significant decrease in B220+ cells in the PB of the Cbfb+/56MFbxo9+/− and Cbfb+/56MFbxo9−/− mice at only three weeks post-transplant (Figure S5A).